Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179

The Molecular Signatures Database Hallmark Gene Set Collection

Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

Adjusting batch effects in microarray expression data using empirical Bayes methods

Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658

Guiding treatment decisions in renal cell carcinoma: the role of biomarkers and clinical factors

Huebner-Resch, I., & Schmidinger, M. (2024) · Current Opinion in Urology · doi:10.1097/mou.0000000000001235 · Cited by 2

Pan-cancer analysis of MET mutation and its association with the efficacy of immune checkpoint blockade

Chen, L., Li, Y., Zhao, H., Huang, J., Yan, H., Lin, X., & Zhao, B. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101450 · Cited by 2

Malaria-derived hemozoin skews dendritic cell responses to bacterial infections by reducing interferon gene-transcription by SWI/SNF-NuRD

Lasaviciute, G., Tariq, K., Sugathan, A., Quin, J. E., Polenkowski, M., Bujila, I., Skorokhod, O. A., Troye‐Blomberg, M., Sverremark‐Ekström, E., & Farrants, A. Ö. (2025) · iScience · doi:10.1016/j.isci.2025.113046 · Cited by 5

Revisiting Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Evidence of Survival Benefit with First-Line Immunotherapy and Targeted Therapy Regimens

Manivasagam, S. S., Aminsharifi, A., & Raman, J. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155543 · Cited by 2

Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy

Reusch, E. M., Peh, K. H., Morgan, R., Momo, H. D., Orren, D. K., Rock, S. L., Pittman, T. A., Neltner, J. H., Kolesar, J., & Villano, J. L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1587752 · Cited by 2

Clinical outcomes and immune contexture in SMARCA4 ‐deficient gastric cancer patients

Sun, M., Gu, Y., Wang, J., Zhang, Z., Ling, Z., Lin, C., Liu, H., Li, R., Shao, F., He, H., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6495 · Cited by 2

The role of pathology in immunotherapy and targeted therapy for renal cell carcinoma

Fanelli, G. N., Roviello, G., & Nesi, G. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001357 · Cited by 2

USP24 stabilizes VDAC2 via deubiquitination to promote apoptosis and ferroptosis in clear cell renal cell carcinoma (ccRCC)

Hao, P., Xu, L., Chen, L., Wan, J., Ding, X., Wu, Y., & Luo, H. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0370 · Cited by 2

Stepwise differentiation from precursor intermediates and distinct Th1 checkpoints promote CD4 Th1 cell differentiation during chronic viral infection

Niu, H., Lin, S., Brown, R. J., Shen, J., Kharel, A., Zhang, Y., Gai, K., Bauer, A., Brown, A. K., Xu, Z., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2522928123 · Cited by 2

Ferroptotic tumor cells reprogram tumor-associated macrophage antigen presentation to enhance the efficacy of immune checkpoint blockade

Sun, J.-L., Chu, Y.-C., Wang, F., Yu, D.-D., Liu, J.-R., Xu, R.-C., Liu, H., Qi, Z., Shi, X., Yu, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102774 · Cited by 2

Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors

Rai, C., Ruan, H., Li, X., Li, W., Jeong, H.-H., Song, C., Liu, P., Chang, Y., Fang, H., Udhaya Kumar., S., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02698-1 · Cited by 2

Obesity-driven metabolic reprogramming and immune dysfunction in renal cancer

Ogbonna, H. N., & Norian, L. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1866875 · Cited by 2

Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation

Beulque, Y., Deleu, A.-L., Punie, K., Wever, L. D., Baldewijns, M. M. L. L., Caruso, S., Couchy, G., Zucman‐Rossi, J., & Beuselinck, B. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.06.013 · Cited by 3

Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer

Eisner, J. R., Beebe, K. D., Mayhew, G. M., Shibata, Y., Guo, Y., Farhangfar, C. J., Farhangfar, F., Uronis, J. M., Mooney, J. M., Milburn, M. V., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0153 · Cited by 2

A Signature Based on Chromatin Regulation and Tumor Microenvironment Infiltration in Clear Cell Renal Cell Carcinoma

Yang, C., Tian, Y., & Lin, Q. (2022) · Epigenomics · doi:10.2217/epi-2022-0202 · Cited by 2

PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma

He, X., Xu, J., Niu, N., Xu, G., Zhu, H., Liu, Z., Mou, Y., Qian, Z., Wang, H., Hu, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1062 · Cited by 2

ROCK2-RNA interaction map reveals multiple biological mechanisms underlying tumor progression in renal cell carcinoma

Hong, Z., Chen, X., Wang, L., Zhou, X., He, H., Zou, G., Liu, Q., & Wang, Y. (2023) · Human Cell · doi:10.1007/s13577-023-00947-x · Cited by 2

Prognostic Factors in Advanced Renal Cell Carcinoma

Takemura, K. N., Navani, V., Heng, D. Y. C., & Ernst, M. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40901-1_10 · Cited by 2

Bayesian multiple instance classification based on hierarchical probit regression

Xiong, D., Park, S., Lim, J., Wang, T., & Wang, X. (2024) · The Annals of Applied Statistics · doi:10.1214/23-aoas1780 · Cited by 2

Prognostic Model and Immune Response of Clear Cell Renal Cell Carcinoma Based on Co-Expression Genes Signature

Yang, D. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102167 · Cited by 2

The immunotherapy-based combination associated score as a robust predictor for outcome and response to combination of immunotherapy and VEGF inhibitors in renal cell carcinoma

Liu, Z., Zang, M., Li, K., Qi, W., Yuan, H., Chen, L., & Zhang, Y. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109210 · Cited by 2

Immunogenic cell death signature predicts survival and reveals the role of VEGFA + Mast cells in lung adenocarcinoma

Zhang, M., Zhou, G., Xu, Y., Wei, B., Liu, Q., Zhang, G., & Chang, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-91401-5 · Cited by 2

Trends and hotspots in targeted therapy resistance research for renal cell carcinoma: a bibliometric and visualization analysis

Wang, Z.-Q., Xie, X., Wang, Z., Tang, P., Chen, J., Xu, J., Zhang, J., Xiao, H., Zheng, C., Jiang, J., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02772-0 · Cited by 2

Targeting Sodium Transport Reveals CHP1 Downregulation as a Novel Molecular Feature of Malignant Progression in Clear Cell Renal Cell Carcinoma: Insights from Integrated Multi-Omics Analyses

Wu, Y., Zhu, R., Chen, J., Liu, X., Huang, G., Zeng, J., Yu, H., Liu, X., & Han, C. (2025) · Biomolecules · doi:10.3390/biom15071019 · Cited by 3

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

Seguí, E., Brasó‐Maristany, F., Pascual, T., Sanfeliu, E., Victoria, I., Saura, C., Hierro, C., López-González, A., Izarzugaza, Y., Ciruelos, E., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105838 · Cited by 2

Latest progress in molecular biology and treatment in genitourinary tumours

del Alba, A. G., Arranz, J. Á., Joaquim Bellmunt, B., Maroto, P., Calvo, O. F., Valderrama, B. P., González‐Billalabeitia, E., Méndez-Vidal, M. J., Cassinello, J., Romero-Laorden, N., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02373-z · Cited by 2

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma

Martini, D. J., Jansen, C. S., Harik, L. R., Evans, S. T., Olsen, T. A., Master, V. A., Kissick, H. T., & Bilen, M. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.793808 · Cited by 2

Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery

McDermott, D. F., & Carducci, M. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01198 · Cited by 2

Is There a Role for Immune Checkpoint Inhibitors in Chordoma?

Assi, T. (2021) · Immunotherapy · doi:10.2217/imt-2021-0066 · Cited by 2

Biomarker: der Weg zur individualisierten Therapie bei Nierenzelltumoren

Zeuschner, P., Zaccagnino, A., & Junker, K. (2021) · Aktuelle Urologie · doi:10.1055/a-1517-6259 · Cited by 2

A Somatic Mutation-Derived LncRNA Signature of Genomic Instability Predicts Prognosis for Patients With Liver Cancer

Guo, C., Zhou, J. H. S., Ma, B., Wang, R., Ge, Y., Wang, Z., Ji, B., Wang, W. T., Zhang, J., & Wang, Z. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.724792 · Cited by 2

Crosstalk Between Four Types of RNA Modification Writers Characterizes the Tumor Immune Microenvironment Infiltration Patterns in Skin Cutaneous Melanoma

Zhang, S., Xiong, Y., Zheng, C., Long, J., Zhou, H., Zeng, Z., Ouyang, Y., & Tang, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.821678 · Cited by 2

Efficacy of Second-Line ICIs Combined with TKIs among Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

Zhang, H., Chen, J., Zhang, X., Zhu, X., Wang, Z., Sun, G., Liang, J., Chen, Y., Shen, Y., Liu, J., et al. (2022) · Immunotherapy · doi:10.2217/imt-2021-0108 · Cited by 2

Establishing a Prognostic Model Based on Three Genomic Instability-related LncRNAs for Clear Cell Renal Cell Cancer

Shen, L., Hua-ling, H., Zhang, S., Dianxi, C., Li, Y., & Li, Q. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.02.005 · Cited by 2

Immune Gene Signature Expression Differs between African American and Caucasian Patients with Renal Cell Carcinoma

Ghatalia, P., Shah, A. J., & Slifker, M. J. (2022) · Kidney Cancer · doi:10.3233/kca-220003 · Cited by 2

Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma

Zhang, C., Qi, F., Zheng, Y., Xia, X., Li, X., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.749119 · Cited by 2

Relationship between body composition and PBRM1 mutations in clear cell renal cell carcinoma: a propensity score matching analysis

Demırel, E., & Dılek, O. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20220415 · Cited by 2

Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer

Han, H. H., Kang, M., Byun, S., & Yun, S. J. (2023) · Journal of Urologic Oncology · doi:10.22465/juo.234600340017 · Cited by 2

The bromodomain acyl-lysine readers in human health and disease

Tchara, P.-E. K., Lashgari, A., & Lambert, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823376-4.00004-5 · Cited by 2

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Hong, J.-H., Kwon, G. Y., Kang, M., Seo, S. I., & Park, S. H. (2024) · Journal of Urologic Oncology · doi:10.22465/juo.234600660033 · Cited by 2

Practical management of renal cell carcinoma: integrating current approaches with advances in bone metastasis treatment

Eremia, I. A., Şerban, B., Popa, M. I. G., Iancu, A., Nica, S., & Cîrstoiu, C. (2024) · EFORT Open Reviews · doi:10.1530/eor-23-0178 · Cited by 2

Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma

Mizuno, R., & Oya, M. (2020) · Kidney Cancer · doi:10.3233/kca-190067 · Cited by 2

Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma

Gao, W., Li, L., Han, X., Liu, S., Li, C., Yu, G., Zhang, L., Zhang, D., Liu, C., Meng, E., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08052-8 · Cited by 2

Prognostic and predictive biomarkers for metastatic renal cell carcinoma

Briggs, L. G., Cone, E. B., Lee, R. J., & Blute, M. L. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.84 · Cited by 2

Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma

Zhao, J., Chang, L., Tu, J., Sun, B., & Wei, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8748434 · Cited by 2

Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors

Tripathi, A., Lin, E., & Agarwal, N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.13 · Cited by 2

Opposing immune and genetic forces shape oncogenic programs in synovial sarcomaPreprint

Jerby‐Arnon, L., Neftel, C., Shore, M. E., McBride, M. J., Haas, B. J., Izar, B., Weissman, H. R., Volorio, A., Boulay, G., Cironi, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724302 · Cited by 2

Integrated analysis of single-cell and transcriptome based RNA-seq multilayer network and WGCNA for construction and validation of an immune cell-related prognostic model in clear cell renal cell carcinomaPreprint

Wu, G., Guo, W., Zhu, S., & Fan, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.15.464475 · Cited by 2

Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma

Labaki, C., Allen, E. M. V., & Choueiri, T. K. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0058 · Cited by 2

Rules of Engagement: The Lymphocyte Receptor Ecosystem in Renal Cell Carcinoma

Krishna, C., & Hakimi, A. A. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0146 · Cited by 2

Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2023) · doi:10.1158/1541-7786.c.6545243 · Cited by 2

Developing an Ideal Risk Stratification Model for Metastatic Renal Cell Carcinoma

Gebrael, G., Fortuna, G. G., & Agarwal, N. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1764 · Cited by 2

TimiGP-Response: the pan-cancer immune landscape associated with response to immunotherapyPreprint

Li, C., Wei, H., Reuben, A., Wang, L., Maitra, A., Zhang, J. J., & Cheng, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.21.600089 · Cited by 2

Is tumor mutational burden predictive of response to immunotherapy?Preprint

Gurjao, C., Tsukrov, D. I., Imakaev, M., Luquette, L. J., & Mirny, L. A. (2024) · eLife · doi:10.7554/elife.87465.2 · Cited by 2

Scalable multimodal mapping of macrophage regulatory architecture by integrating optical and transcriptomic pooled screensPreprint

Kudo, T., Lopez, R., Meireles, A. M., Rios, A., Coelho, P. P., Chandrasekar, V., Lam, D. C., Huetter, J.-C., Ota, M., Rozenblatt–Rosen, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.728345 · Cited by 2

Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy

Song, P., Wusiman, D., Li, W., Guo, L., Ying, J., Gao, S., & He, J. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000477 · Cited by 1

Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer

Измайлов, А. А., Радимович, Р. Р., Sultanbayev, A. V., Меньшиков, К. В., Gilyazova, I. R., Zabelin, V. M., & Izmailov, A. A. (2023) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2023-22-4-109-117 · Cited by 1

PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study

Chang, Q., Sun, J., Zhao, S., Li, L., Zhang, N., Yan, L., Fan, Y., & Liu, J. (2023) · Aging · doi:10.18632/aging.205261 · Cited by 1

Clinical Implications of a Six-Protein Signature in Bone Metastasis of Renal Cell Carcinoma

Liu, Z., Mao, H., Chu, D., Liang, Q., & Wang, J. (2024) · Journal of Cancer · doi:10.7150/jca.88612 · Cited by 1

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy

Wang, K., Zhang, Y., Su, Z., Wang, B., Zhou, Y., Tong, X., Xie, C., Luo, X., Zhang, S., & Zheng, M. (2025) · Cancer Medicine · doi:10.1002/cam4.70556 · Cited by 1

Metabolites and metabolic pathway reactions links to sensitization of immunotherapy in pan-cancer

Yu, S., Gao, Y., Zhao, F., Zhou, J., & Zhang, J. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200933 · Cited by 3

Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma

Arai, M., Tanaka, N., Takamatsu, K., Murakami, T., Mikami, S., Imamura, T., Nakamura, K., Nishihara, H., & Oya, M. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04020-4 · Cited by 1

The role of programmed cell death in renal cancer: a bibliometric perspective (1998–2024)

Hong, L., Zhao, C., Wu, T., Hu, X., Li, X., & Lü, L. (2025) · Discover Oncology · doi:10.1007/s12672-025-02610-3 · Cited by 1

PD‐L1 Expression is Mediated by microRNA Processing, Wnt/β‐Catenin Signaling, and Chemotherapy in Wilms Tumor

Tiburcio, P. D. B., Desai, K. K., Warne, A., Nabbi, A., Zhou, S., Reiff, S. D., Campbell, M. E., Amatruda, J. F., & Chen, K. S.-M. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31852 · Cited by 1

Prevalence of Germline Variants in Advanced Renal Cell Carcinoma in North India

Nagpal, C., Divakar, M. K., Baskarane, H., Tansir, G., Jain, R. R., Sharma, A., Sahoo, R. K., Bakhshi, S., Gupta, I., Minocha, S., et al. (2025) · JCO Global Oncology · doi:10.1200/go-25-00137 · Cited by 1

IC2Bert: masked gene expression pretraining and supervised fine tuning for robust immune checkpoint blockade (ICB) response prediction

Park, S., Kim, S., & Jiang, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-14166-x · Cited by 1

Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture

Mogi, M., Kawase, K., Tanaka, H. Y., Miyata, S., Takemoto, S., Ikeda, H., Katayama, E., Nakamura, Y., Kojima, R., Morinaga, T., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03233-9 · Cited by 1

Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohort

Glienke, M., Himmelsbach, R., Zirngibl, M., Metzger, P., Kühn, J., Miething, C., Sigle, A., Gratzke, C., Nientiedt, C., Rassner, M. P., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1688779 · Cited by 1

The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities

Bongiovanni, A., Conte, P., Conteduca, V., Landriscina, M., Lorenzo, G. D., & Cognetti, F. (2025) · Current Oncology · doi:10.3390/curroncol32120690 · Cited by 2

The fall of the genome protectors triad: PBRM1, SETD2, and BAP1’s impact on metabolism and immunity in clear cell renal cell carcinoma

Johnson, M., & Turcotte, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1713830 · Cited by 2

SMARCA4-deficient carcinoma of the head and neck region: report of 8 new sinonasal and non-sinonasal cases and literature review

Farkas, M., Agaimy, A., Švajdler, M., Hauer, L., Martínek, P., Vaněček, T., Pivovarčíková, K., Prchlíková, B., Simpson, R. H. W., Gočárová, K., et al. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04459-5 · Cited by 1

T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses

Gilmour, C., Delaney, E., Parthasarathy, P. B., Roy, D., Ta, H. M., Zakeri, A., Grandez, P. E., Patnaik, S., Zhang, K., Juric, I., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci195668 · Cited by 3

Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL

Jixiang, B., Chen, X., Xiaoxuan, P., Mingli, S., Jieru, H., & Shuhui, W. (2026) · Discover Oncology · doi:10.1007/s12672-026-04707-9 · Cited by 2

Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinoma

Zhang, Y., Zhu, Y., Liu, Z., Li, H., Zhong, B., Cui, X., Kong, Y., & Lu, H. J. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.27 · Cited by 1

Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCC

He, H., Liu, X.-D., & Jonasch, E. W. (2026) · MedScience · doi:10.1007/s11684-025-1136-4 · Cited by 1

First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies

Kridis, W. B., & Khanfir, A. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01535-6 · Cited by 1

NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma

Pan, Y., Wu, R., Zhu, X., Hu, X., Cheng, J., & Kong, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1914332 · Cited by 1

Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation

Mathews, P., Neiditz, H., Hollenbeck, P., Rajkumar, J., Schoen, M. W., Pachynski, R. K., & Knoche, E. M. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102645 · Cited by 1

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study

McDermott, D. F., Signoretti, S., Lee, J.-L., Donskov, F. N., Tykodi, S. S., Tomczak, P., Bjarnason, G. A., Larkin, J., Kochenderfer, M. D., Gafanov, R. A., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.09.011 · Cited by 1

Research Progress of the Treatment of PD-1 Immune CheckpointInhibitors in Oral Squamous Cell Carcinoma

Wang, Y.-T., Qian, S., & Li, K. (2020) · Journal of Oncology Research · doi:10.30564/jor.v2i2.2429 · Cited by 1

Genetic analysis of primary renal cell carcinoma to determine treatment approaches

Stühler, V., Rausch, S., Stenzl, A., & Bedke, J. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1874822 · Cited by 1

Defining an Individualized Treatment Strategy for Metastatic Renal Cancer

Parikh, M., Harris, J. A. K., Alpajaro, S. I., Lara, P. N., & Evans, C. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-24378-4_25 · Cited by 1

Identification and Validation of Co-Expressed Immune-Related Gene Signature Affecting the Pattern of Immune Infiltrating in Esophageal Cancer

Dong, B., Cheng, R., Zeng, H., Chen, L., & Zhou, L. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220705105906 · Cited by 1

Multiple primary malignancies with complex genomic profiling

Hinduja, S., Mahmood, O., Khan, A. A., & Lin, Y. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100185 · Cited by 1

A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma

Lin, L., Wu, X., Zhu, J.-M., Chen, S., Chen, Y., Lin, F., Xue, X., Wei, Y., Xu, N., Zheng, Q., et al. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220926123923 · Cited by 1

Tratamiento del cáncer de riñón metastásico

Dumont, C., Flippot, R., Bonnet, C., Gauthier, H., Albiges, L. K., & Culine, S. (2022) · EMC - Urología · doi:10.1016/s1761-3310(22)46756-9 · Cited by 1

Designer Microbes: Oncotherapy Approach

Das, J. K., & Arunima, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_10 · Cited by 1

Advanced CT Imaging, Radiomics, and Artificial Intelligence to Evaluate Immune Checkpoint Inhibitors’ Effects on Metastatic Renal Cell Carcinoma

Greco, F., Zobel, B. B., Gennaro, G. D., & Mallio, C. A. (2023) · Applied Sciences · doi:10.3390/app13063779 · Cited by 1

Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma

Chen, M., Li, P., Yao, H., Liu, F., Fu, L., Wang, Y., Zhu, J., Xu, Q., Liang, H., Zhou, Y., et al. (2023) · Translational Andrology and Urology · doi:10.21037/tau-23-21 · Cited by 1

Estimation of CD8 Parameter Level in Thalassemia Patients

Abd-Alsahib, S., Abd-Alhussein, A., & Jameel, Y. M. (2022) · Journal of Techniques · doi:10.51173/jt.v4i33.686 · Cited by 1

Targeting of the SWI/SNF chromatin remodeling complex in cancer therapy

Nemtsova, M. V., & Bure, I. V. (2023) · Advances in molecular oncology · doi:10.17650/2313-805x-2023-10-1-8-17 · Cited by 1

Transmembrane serine protease 2, a SARS-CoV-2 internalization protease, correlates with clinical outcome, molecular features, and immunotherapy response in colorectal cancer

Zhu, C., Wu, J., Shelat, V. G., Sayagués, J. M., Yamamoto, S., Li, Y., & He, X. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-641 · Cited by 1

Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinoma

Hou, S., Gu, T., Shi, Y., Huang, Y., Yao, J., Luo, P., Cao, M., Zhang, J., Lin, A., & Zhu, W. (2023) · Cancer Biomarkers · doi:10.3233/cbm-230226 · Cited by 1

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy

Tang, C., & Yen, C. (2023) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-23-00026 · Cited by 1

Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma

Yoshida, T., Sakai, K., Kaibori, M., Ishida, M., Tanaka, S., Kubo, S., Nakai, T., Velasco, M. A. D., Matsushima, H., Tsuta, K., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14257 · Cited by 1

The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers

Mustafa, S., Jansen, C. S., Jani, Y. C., Evans, S., Zhuang, T., Brown, J. T., Nazha, B., Master, V. A., & Bilen, M. A. (2024) · Biomarker Insights · doi:10.1177/11772719241254179 · Cited by 1

Exploring the role of CD8 + T cells in clear renal cell carcinoma metastasis

Chen, Y., Shen, J., Ling, C., Liang, Z.-F., Huang, S., Lin, W., Qin, Y., Meng, L.-Z., & Luo, Y. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13819

Establishment and validation of a novel disulfidptosis-related immune checkpoint gene signature in clear cell renal cell carcinoma

Du, L., Zhang, N., Wang, B., Cheng, W., & Wen, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01105-x · Cited by 1

Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer

Ahluwalia, P. K., Mondal, A. K., Vashisht, A., Singh, H., Alptekin, A., Ballur, K., Omar, N., Ahluwalia, M., Jones, K., Barrett, A., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06034-4 · Cited by 1

Exploring the Prognostic Value of Tumour‐Associated Genes in Clear Cell Renal Cell Carcinoma Through Single‐Cell RNA Sequencing Insights

Fu, T., Zhang, X., Liu, Y., Wu, J., Liu, X., Lu, B., Huang, Y. F., Yang, L., & Zhan, Y. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70297 · Cited by 1

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852

Highlights from Recent Cancer Literature

(2018) · Cancer Research · doi:10.1158/0008-5472.1373.78.6

PBRM1 loss promotes tumour response to immunotherapy

Otto, G. P. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.7 · Cited by 5

Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.

Miao, D., Margolis, C. A., Martini, D. J., Mullane, S. A., Cullen, D., Horak, C. E., Wind‐Rotolo, M., Hellmann, M. D., Voss, M. H., Motzer, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3016 · Cited by 4

Abstract B48: PBRM1 loss promotes resistance to immunotherapy in RCC

Liu, X., Kong, W., Hoang, A. G., Zhang, X., Zhou, L., Pilie, P. G., Isgandrova, S., Moczygemba, M. M., & Jonasch, E. W. (2020) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm18-b48